Literature DB >> 25048968

Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report.

Mohammad Hashemi1, Maryam Sheybani-Nasab, Majid Naderi, Fatemeh Roodbari, Mohsen Taheri.   

Abstract

MicroRNAs (miRNAs), a class of non-coding RNAs, bind to the 3' untranslated regions (UTRs) of mRNAs, where they interfere with translation of genes and are implicated in the pathogenesis of diverse diseases. In the present study, we evaluate the impact of rs16917496 polymorphism within the miR-502 miRNA seed region at the 3'UTR of SEDT8 on childhood acute lymphoblastic leukemia (ALL). This case-control study was done on 75 ALL and 115 healthy children. Genotyping of rs16917496 C/T polymorphism was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The results showed that CT as well as CT + TT decreased the risk of ALL in comparison with CC genotype (odds ratio (OR) = 0.29, 95 % confidence intervals (95 % CI) = 0.11-0.78, P = 0.014 and OR = 0.31, 95 % CI = 0.12-0.82, P = 0.016, respectively). Our results demonstrated that SETD8 rs16917496 C/T polymorphism was associated with decreased risk of developing pediatric ALL in Zahedan, southeast Iran. Larger studies with different ethnicities are desired to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048968     DOI: 10.1007/s13277-014-2359-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability.

Authors:  Sabrina I Houston; Kirk J McManus; Melissa M Adams; Jennifer K Sims; Phillip B Carpenter; Michael J Hendzel; Judd C Rice
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

2.  An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.

Authors:  Fengju Song; Hong Zheng; Ben Liu; Sheng Wei; Hongji Dai; Lina Zhang; George A Calin; Xishan Hao; Qingyi Wei; Wei Zhang; Kexin Chen
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

3.  Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression.

Authors:  Shumin Wu; Weiping Wang; Xiangduo Kong; Lauren M Congdon; Kyoko Yokomori; Marc W Kirschner; Judd C Rice
Journal:  Genes Dev       Date:  2010-10-21       Impact factor: 11.361

4.  The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells.

Authors:  Mathieu Tardat; Julien Brustel; Olivier Kirsh; Christine Lefevbre; Mary Callanan; Claude Sardet; Eric Julien
Journal:  Nat Cell Biol       Date:  2010-10-17       Impact factor: 28.824

5.  Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1.

Authors:  N Kalakonda; W Fischle; P Boccuni; N Gurvich; R Hoya-Arias; X Zhao; Y Miyata; D Macgrogan; J Zhang; J K Sims; J C Rice; S D Nimer
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

6.  SET8-mediated methylations of histone H4 lysine 20 mark silent heterochromatic domains in apicomplexan genomes.

Authors:  Céline F Sautel; Dominique Cannella; Olivier Bastien; Sylvie Kieffer; Delphine Aldebert; Jérôme Garin; Isabelle Tardieux; Hassan Belrhali; Mohamed-Ali Hakimi
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

7.  Modulation of p53 function by SET8-mediated methylation at lysine 382.

Authors:  Xiaobing Shi; Ioulia Kachirskaia; Hiroshi Yamaguchi; Lisandra E West; Hong Wen; Evelyn W Wang; Sucharita Dutta; Ettore Appella; Or Gozani
Journal:  Mol Cell       Date:  2007-08-17       Impact factor: 17.970

8.  Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.

Authors:  Junko H Ohyashiki; Tomohiro Umezu; Chiaki Kobayashi; Ryoko S Hamamura; Masami Tanaka; Masahiko Kuroda; Kazuma Ohyashiki
Journal:  BMC Res Notes       Date:  2010-12-24

9.  Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.

Authors:  E Ellinghaus; M Stanulla; G Richter; D Ellinghaus; G te Kronnie; G Cario; G Cazzaniga; M Horstmann; R Panzer Grümayer; H Cavé; J Trka; O Cinek; A Teigler-Schlegel; A ElSharawy; R Häsler; A Nebel; B Meissner; T Bartram; F Lescai; C Franceschi; M Giordan; P Nürnberg; B Heinzow; M Zimmermann; S Schreiber; M Schrappe; A Franke
Journal:  Leukemia       Date:  2011-11-11       Impact factor: 11.528

10.  Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population.

Authors:  Jiali Xu; Zhiqiang Yin; Wen Gao; Lingxiang Liu; Yongmei Yin; Ping Liu; Yongqian Shu
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more
  12 in total

1.  IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Mohsen Taheri
Journal:  Tumour Biol       Date:  2016-01-21

2.  FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

3.  The dynamic conformational landscape of the protein methyltransferase SETD8.

Authors:  Shi Chen; Rafal P Wiewiora; Fanwang Meng; Nicolas Babault; Anqi Ma; Wenyu Yu; Kun Qian; Hao Hu; Hua Zou; Junyi Wang; Shijie Fan; Gil Blum; Fabio Pittella-Silva; Kyle A Beauchamp; Wolfram Tempel; Hualiang Jiang; Kaixian Chen; Robert J Skene; Yujun George Zheng; Peter J Brown; Jian Jin; Cheng Luo; John D Chodera; Minkui Luo
Journal:  Elife       Date:  2019-05-13       Impact factor: 8.140

4.  Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk.

Authors:  Sara Sanaei; Mohammad Hashemi; Maryam Rezaei; Seyed Mehdi Hashemi; Gholamreza Bahari; Saeid Ghavami
Journal:  Biomed Rep       Date:  2016-05-23

5.  Association between Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphisms and Susceptibility to Childhood Acute Lymphoblastic Leukemia in an Iranian Population.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Mohsen Taheri
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

6.  Polymorphism (rs16917496) at the miR-502 Binding Site of the Lysine Methyltransferase 5A (SET8) and Its Correlation with Colorectal Cancer in Iranians.

Authors:  Meysam Mosallayi; Miganoosh Simonian; Sharifeh Khosravi; Ahmad Reza Salehi; Mahsa Khodadoostan; Vahid Sebghatollahi; Azar Baradaran; Rasoul Salehi
Journal:  Adv Biomed Res       Date:  2017-07-14

Review 7.  The emerging role of lysine methyltransferase SETD8 in human diseases.

Authors:  Ciro Milite; Alessandra Feoli; Monica Viviano; Donatella Rescigno; Agostino Cianciulli; Amodio Luca Balzano; Antonello Mai; Sabrina Castellano; Gianluca Sbardella
Journal:  Clin Epigenetics       Date:  2016-09-22       Impact factor: 6.551

8.  DROSHA rs642321 Polymorphism Influence Susceptibility to Childhood Acute Lymphoblastic Leukemia: A Preliminary Report.

Authors:  Mohammad Hashemi; Seyed-Shahaboddin Hasani; Majid Naderi
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec

9.  A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.

Authors:  Ben Liu; Xining Zhang; Fengju Song; Qun Liu; Hongji Dai; Hong Zheng; Ping Cui; Lina Zhang; Wei Zhang; Kexin Chen
Journal:  Oncotarget       Date:  2016-06-07

10.  An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.

Authors:  Vanessa Szablewski; Caroline Bret; Alboukadel Kassambara; Julie Devin; Guillaume Cartron; Valérie Costes-Martineau; Jérôme Moreaux
Journal:  Oncotarget       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.